Natural killer (NK) cells represent a subset of CD3- CD7+ CD56+/dim lymphocytes with cytotoxic and suppressor activity against virus-infected cells and cancer cells. The overall potential of NK cells has brought them to the spotlight of targeted immunotherapy in solid and hematological malignancies, including multiple myeloma (MM). Nonetheless, NK cells are subjected to a variety of cancer defense mechanisms, leading to impaired maturation, chemotaxis, target recognition, and killing. This review aims to summarize the available and most current knowledge about cancer-related impairment of NK cell function occurring in MM.

Faculty of Medicine University of Ostrava Ostrava Czechia

Faculty of Science University of Ostrava Ostrava Czechia

Hematooncology Clinic University Hospital Ostrava Ostrava Czechia

Zobrazit více v PubMed

Rajkumar SV. Multiple Myeloma: 2020 Update on Diagnosis, Risk-Stratification And Management. Am J Hematol (2020) 95(5):548–67. doi:10.1002/ajh.25791. PubMed

Kyle RA, Rajkumar SV. Treatment of Multiple Myeloma: A Comprehensive Review. Clin Lymph Myeloma (2009) 9(4):278–88. doi: 10.3816/CLM.2009.n.056 PubMed DOI PMC

Blade J, de Larrea CF, Rosinol L. Extramedullary Involvement in Multiple Myeloma. Haematologica (2012) 97(11):1618–9. doi: 10.3324/haematol.2012.078519 PubMed DOI PMC

Bladé J, Fernández de Larrea C, Rosiñol L, Cibeira MT, Jiménez R, Powles R. Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach. J Clin Oncol Off J Am Soc Clin Oncol (2011) 29(28):3805–12. doi: 10.1200/JCO.2011.34.9290 PubMed DOI

Jelinek T, Sevcikova T, Zihala D, Popkova T, Kapustova V, Broskevicova L, et al. . Limited Efficacy of Daratumumab in Multiple Myeloma With Extramedullary Disease. Leukemia (2021), 1–4. doi: 10.1038/s41375-021-01343-w Published online July 10. PubMed DOI

Sevcikova S, Minarik J, Stork M, Jelinek T, Pour L, Hajek R. Extramedullary Disease in Multiple Myeloma - Controversies and Future Directions. Blood Rev (2019) 36:32–9. doi: 10.1016/j.blre.2019.04.002 PubMed DOI

Besse L, Sedlarikova L, Greslikova H, Kupska R, Almasi M, Penka M, et al. . Cytogenetics in Multiple Myeloma Patients Progressing Into Extramedullary Disease. Eur J Haematol (2016) 97(1):93–100. doi: 10.1111/ejh.12688 PubMed DOI

Shimasaki N, Jain A, Campana D. NK Cells for Cancer Immunotherapy. Nat Rev Drug Discov (2020) 19(3):200–18. doi: 10.1038/s41573-019-0052-1 PubMed DOI

Lamb MG, Rangarajan HG, Tullius BP, Lee DA. Natural Killer Cell Therapy for Hematologic Malignancies: Successes, Challenges, and the Future. Stem Cell Res Ther (2021) 12:1–19. doi: 10.1186/s13287-021-02277-x PubMed DOI PMC

Ben-Shmuel A, Biber G, Barda-Saad M. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy? Front Immunol (2020) 11:275. doi: 10.3389/fimmu.2020.00275 PubMed DOI PMC

Heinze A, Grebe B, Bremm M, Huenecke S, Munir TA, Graafen L, et al. . The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their Ex Vivo Expansion and Cytotoxic Potential Against Neuroblastoma: Perspective for Optimized Immunotherapy Post Haploidentical Stem Cell Transplantation. Front Immunol (2019) 10. doi: 10.3389/fimmu.2019.02816 PubMed DOI PMC

Khan AM, Devarakonda S, Bumma N, Chaudhry M, Benson DM. Potential of NK Cells in Multiple Myeloma Therapy. Expert Rev Hematol (2019) 12(6):425–35. doi: 10.1080/17474086.2019.1617128 PubMed DOI

Paul S, Lal G. The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy. Front Immunol (2017) 8. doi: 10.3389/fimmu.2017.01124 PubMed DOI PMC

Ames E, Murphy WJ. Advantages and Clinical Applications of Natural Killer Cells in Cancer Immunotherapy. Cancer Immunol Immunother CII (2014) 63:21–8. doi: 10.1007/s00262-013-1469-8 PubMed DOI PMC

Basar R, Daher M, Rezvani K. Next-Generation Cell Therapies: The Emerging Role of CAR-NK Cells. Blood Adv (2020) 4(22):5868–76. doi: 10.1182/bloodadvances.2020002547 PubMed DOI PMC

Jaiswal SR, Zaman S, Nedunchezhian M, Chakrabarti A, Bhakuni P, Ahmed M, et al. . CD56-Enriched Donor Cell Infusion After Post-Transplantation Cyclophosphamide for Haploidentical Transplantation of Advanced Myeloid Malignancies Is Associated With Prompt Reconstitution of Mature Natural Killer Cells and Regulatory T Cells With Reduced Incidence of Acute Graft Versus Host Disease: A Pilot Study. Cytother (2017) 19(4):531–42. doi: 10.1016/j.jcyt.2016.12.006 PubMed DOI

Alici E, Sutlu T, Björkstrand B, Gilljam M, Stellan B, Nahi H, et al. . Autologous Antitumor Activity by NK Cells Expanded From Myeloma Patients Using GMP-Compliant Components. Blood (2008) 111(6):3155–62. doi: 10.1182/blood-2007-09-110312 PubMed DOI

Alfarra H, Weir J, Grieve S, Reiman T. Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy. Front Immunol (2020) 11:575609. doi: 10.3389/fimmu.2020.575609 PubMed DOI PMC

Chen Y, Lu D, Churov A, Fu R. Research Progress on NK Cell Receptors and Their Signaling Pathways. Mediators Inflamm (2020) 2020:e6437057. doi: 10.1155/2020/6437057 PubMed DOI PMC

Tognarelli S, Wirsching S, von Metzler I, Rais B, Jacobs B, Serve H, et al. . Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma. Front Immunol (2018) 9:2743. doi: 10.3389/fimmu.2018.02743 PubMed DOI PMC

Szczepanski MJ, Szajnik M, Welsh A, Foon KA, Whiteside TL, Boyiadzis M. Interleukin-15 Enhances Natural Killer Cell Cytotoxicity in Patients With Acute Myeloid Leukemia by Upregulating the Activating NK Cell Receptors. Cancer Immunol Immunother CII (2010) 59(1):73–9. doi: 10.1007/s00262-009-0724-5 PubMed DOI PMC

Alonso Fernández R. Restoring NK Cell Activities in Multiple Myeloma With IL-15 Receptor Agonist NKTR-255. In: ASH (2020). Available at: https://ash.confex.com/ash/2020/webprogram/Paper140395.html (Accessed April 15, 2021).

Van Elssen C, van Gorkom G, Voorter C, von dem Borne P, Meijer E, Wieten L, et al. . Haploidentical Transplantation in Patients With Multiple Myeloma Making Use of Natural Killer Cell Alloreactive Donors. Ann Hematol (2021) 100(1):181–7. doi: 10.1007/s00277-020-04303-z PubMed DOI PMC

van de Donk NWCJ, Moreau P, Plesner T, Palumbo A, Gay F, Laubach JP, et al. . Clinical Efficacy and Management of Monoclonal Antibodies Targeting CD38 and SLAMF7 in Multiple Myeloma. Blood (2016) 127(6):681–95. doi: 10.1182/blood-2015-10-646810 PubMed DOI

Zahavi D, Weiner L. Monoclonal Antibodies in Cancer Therapy. Antibodies (2020) 9:1–20. doi: 10.3390/antib9030034 PubMed DOI PMC

Jelinek T, Hajek R. Monoclonal Antibodies - A New Era in the Treatment of Multiple Myeloma. Blood Rev (2016) 30(2):101–10. doi: 10.1016/j.blre.2015.08.004 PubMed DOI

Sherbenou DW, Mark TM, Forsberg P. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future. Clin Lymphoma Myeloma Leuk (2017) 17(9):545–54. doi: 10.1016/j.clml.2017.06.030 PubMed DOI

Moreno L, Perez C, Zabaleta A, Manrique I, Alignani D, Ajona D, et al. . The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma. Clin Cancer Res Off J Am Assoc Cancer Res (2019) 25(10):3176–87. doi: 10.1158/1078-0432.CCR-18-1597 PubMed DOI

Raab MS, Engelhardt M, Blank A, Goldschmidt H, Agis H, Blau IW, et al. . MOR202, a Novel Anti-CD38 Monoclonal Antibody, in Patients With Relapsed or Refractory Multiple Myeloma: A First-in-Human, Multicentre, Phase 1-2a Trial. Lancet Haematol (2020) 7(5):e381–94. doi: 10.1016/S2352-3026(19)30249-2 PubMed DOI

Pascal V, Schleinitz N, Brunet C, Ravet S, Bonnet E, Lafarge X, et al. . Comparative Analysis of NK Cell Subset Distribution in Normal and Lymphoproliferative Disease of Granular Lymphocyte Conditions. Eur J Immunol (2004) 34(10):2930–40. doi: 10.1002/eji.200425146 PubMed DOI

Dogra P, Rancan C, Ma W, Toth M, Senda T, Carpenter DJ, et al. . Tissue Determinants of Human NK Cell Development, Function, and Residence. Cell (2020) 180(4):749–763.e13. doi: 10.1016/j.cell.2020.01.022 PubMed DOI PMC

Carrega P, Ferlazzo G. Natural Killer Cell Distribution and Trafficking in Human Tissues. Front Immunol (2012) 3. doi: 10.3389/fimmu.2012.00347 PubMed DOI PMC

Yu J, Freud AG, Caligiuri MA. Location and Cellular Stages of NK Cell Development. Trends Immunol (2013) 34(12):573–82. doi: 10.1016/j.it.2013.07.005 PubMed DOI PMC

Scoville SD, Freud AG, Caligiuri MA. Modeling Human Natural Killer Cell Development in the Era of Innate Lymphoid Cells. Front Immunol (2017) 8. doi: 10.3389/fimmu.2017.00360 PubMed DOI PMC

Abel AM, Yang C, Thakar MS, Malarkannan S. Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front Immunol (2018) 9. doi: 10.3389/fimmu.2018.01869 PubMed DOI PMC

Kalland T. Generation of Natural Killer Cells From Bone Marrow Precursors. vitro Immunol (1986) 57(4):493–8. PubMed PMC

Dmytrus J, Matthes-Martin S, Pichler H, Worel N, Geyeregger R, Frank N, et al. . Multi-Color Immune-Phenotyping of CD34 Subsets Reveals Unexpected Differences Between Various Stem Cell Sources. Bone Marrow Transplant (2016) 51(8):1093–100. doi: 10.1038/bmt.2016.88 PubMed DOI

Görgens A, Radtke S, Möllmann M, Cross M, Dürig J, Horn PA, et al. . Revision of the Human Hematopoietic Tree: Granulocyte Subtypes Derive From Distinct Hematopoietic Lineages. Cell Rep (2013) 3(5):1539–52. doi: 10.1016/j.celrep.2013.04.025 PubMed DOI

Carotta S, Pang SHM, Nutt SL, Belz GT. Identification of the Earliest NK-Cell Precursor in the Mouse BM. Blood (2011) 117(20):5449–52. doi: 10.1182/blood-2010-11-318956 PubMed DOI

Renoux VM, Zriwil A, Peitzsch C, Michaëlsson J, Friberg D, Soneji S, et al. . Identification of a Human Natural Killer Cell Lineage-Restricted Progenitor in Fetal and Adult Tissues. Immun (2015) 43(2):394–407. doi: 10.1016/j.immuni.2015.07.011 PubMed DOI

Boos MD, Ramirez K, Kee BL. Extrinsic and Intrinsic Regulation of Early Natural Killer Cell Development. Immunol Res (2008) 40(3):193–207. doi: 10.1007/s12026-007-8006-9 PubMed DOI

Fathman JW, Bhattacharya D, Inlay MA, Seita J, Karsunky H, Weissman IL. Identification of the Earliest Natural Killer Cell–Committed Progenitor in Murine Bone Marrow. Blood (2011) 118(20):5439–47. doi: 10.1182/blood-2011-04-348912 PubMed DOI PMC

Ziegler S, Weiss E, Schmitt AL, Schlegel J, Burgert A, Terpitz U, et al. . CD56 Is a Pathogen Recognition Receptor on Human Natural Killer Cells. Sci Rep (2017) 7(1):6138. doi: 10.1038/s41598-017-06238-4 PubMed DOI PMC

Mace EM, Hsu AP, Monaco-Shawver L, Makedonas G, Rosen JB, Dropulic L, et al. . Mutations in GATA2 Cause Human NK Cell Deficiency With Specific Loss of the CD56bright Subset. Blood (2013) 121(14):2669–77. doi: 10.1182/blood-2012-09-453969 PubMed DOI PMC

Lysakova-Devine T, O’Farrelly C. Tissue-Specific NK Cell Populations and Their Origin. J Leukoc Biol (2014) 96(6):981–90. doi: 10.1189/jlb.1RU0514-241R PubMed DOI

Aggarwal N, Swerdlow SH, TenEyck SP, Boyiadzis M, Felgar RE. Natural Killer Cell (NK) Subsets and NK-Like T-Cell Populations in Acute Myeloid Leukemias and Myelodysplastic Syndromes. Cytometry B Clin Cytom (2016) 90(4):349–57. doi: 10.1002/cyto.b.21349 PubMed DOI

Poli A, Michel T, Thérésine M, Andrès E, Hentges F, Zimmer J. CD56bright Natural Killer (NK) Cells: An Important NK Cell Subset. Immunol (2009) 126(4):458–65. doi: 10.1111/j.1365-2567.2008.03027.x PubMed DOI PMC

Campbell KS, Hasegawa J. NK Cell Biology: An Update and Future Directions. J Allergy Clin Immunol (2013) 132(3):536–44. doi: 10.1016/j.jaci.2013.07.006 PubMed DOI PMC

Bassani B, Baci D, Gallazzi M, Poggi A, Bruno A, Mortara L. Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities Into Potent Anti-Tumor Effects. Cancers (2019) 11(4):461. doi: 10.3390/cancers11040461 PubMed DOI PMC

Cooper MA, Fehniger TA, Caligiuri MA. The Biology of Human Natural Killer-Cell Subsets. Trends Immunol (2001) 22(11):633–40. doi: 10.1016/s1471-4906(01)02060-9 PubMed DOI

Lopez-Vergès S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, et al. . CD57 Defines a Functionally Distinct Population of Mature NK Cells in the Human CD56dimCD16+ NK-Cell Subset. Blood (2010) 116(19):3865–74. doi: 10.1182/blood-2010-04-282301 PubMed DOI PMC

Mavilio D, Lombardo G, Benjamin J, Kim D, Follman D, Marcenaro E, et al. . Characterization of CD56–/CD16+ Natural Killer (NK) Cells: A Highly Dysfunctional NK Subset Expanded in HIV-Infected Viremic Individuals. Proc Natl Acad Sci USA (2005) 102(8):2886–91. doi: 10.1073/pnas.0409872102 PubMed DOI PMC

Milush JM, López-Vergès S, York VA, Deeks SG, Martin JN, Hecht FM, et al. . CD56negCD16+NK Cells are Activated Mature NK Cells With Impaired Effector Function During HIV-1 Infection. Retrovirology (2013) 10(1):158. doi: 10.1186/1742-4690-10-158 PubMed DOI PMC

Hayakawa Y, Smyth MJ. CD27 Dissects Mature NK Cells Into Two Subsets With Distinct Responsiveness and Migratory Capacity. J Immunol (2006) 176(3):1517–24. doi: 10.4049/jimmunol.176.3.1517 PubMed DOI

Fu B, Wang F, Sun R, Ling B, Tian Z, Wei H. CD11b and CD27 Reflect Distinct Population and Functional Specialization in Human Natural Killer Cells. Immunol (2011) 133(3):350–9. doi: 10.1111/j.1365-2567.2011.03446.x PubMed DOI PMC

Horowitz A, Strauss-Albee DM, Leipold M, Kubo J, Nemat-Gorgani N, Dogan OC, et al. . Genetic and Environmental Determinants of Human NK Cell Diversity Revealed by Mass Cytometry. Sci Transl Med (2013) 5(208):208ra145. doi: 10.1126/scitranslmed.3006702 PubMed DOI PMC

Nicholson SE, Keating N, Belz GT. Natural Killer Cells and Anti-Tumor Immunity. Mol Immunol (2019) 110:40–7. doi: 10.1016/j.molimm.2017.12.002 PubMed DOI

Sungur CM, Murphy WJ. Positive and Negative Regulation by NK Cells in Cancer. Crit Rev Oncog (2014) 19(0):57–66. doi: 10.1615/CritRevOncog.2014010805 PubMed DOI PMC

Peng H, Tian Z. Natural Killer Cell Memory: Progress and Implications. Front Immunol (2017) 8:1143. doi: 10.3389/fimmu.2017.01143 PubMed DOI PMC

Yoon SR, Kim TD, Choi I. Understanding of Molecular Mechanisms in Natural Killer Cell Therapy. Exp Mol Med (2015) 47(2):e141–1. doi: 10.1038/emm.2014.114 PubMed DOI PMC

Konjević G, Vuletić A, Martinović KM, Džodić R. The Role of Activating and Inhibitory NK Cell Receptors in Antitumor Immune Response. IntechOpen (2017) 69:49–65. doi: 10.5772/intechopen.69729 DOI

Maria AD, Bozzano F, Cantoni C, Moretta L. Revisiting Human Natural Killer Cell Subset Function Revealed Cytolytic CD56dimCD16+ NK Cells as Rapid Producers of Abundant IFN-γ on Activation. Proc Natl Acad Sci (2011) 108(2):728–32. doi: 10.1073/pnas.1012356108 PubMed DOI PMC

Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of Human NK-Cell Cytokine and Chemokine Production by Target Cell Recognition. Blood (2010) 115(11):2167–76. doi: 10.1182/blood-2009-08-238469 PubMed DOI PMC

Street SE, Cretney E, Smyth MJ. Perforin and Interferon-Gamma Activities Independently Control Tumor Initiation, Growth, and Metastasis. Blood (2001) 97(1):192–7. doi: 10.1182/blood.v97.1.192 PubMed DOI

Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SEA, Yagita H, et al. . Activation of NK Cell Cytotoxicity. Mol Immunol (2005) 42(4):501–10. doi: 10.1016/j.molimm.2004.07.034 PubMed DOI

Topham NJ, Hewitt EW. Natural Killer Cell Cytotoxicity: How do They Pull the Trigger? Immunol (2009) 128(1):7–15. doi: 10.1111/j.1365-2567.2009.03123.x PubMed DOI PMC

Guicciardi ME, Gores GJ. Life and Death by Death Receptors. FASEB J (2009) 23(6):1625–37. doi: 10.1096/fj.08-111005 PubMed DOI PMC

Kumar R, Herbert PE, Warrens AN. An Introduction to Death Receptors in Apoptosis. Int J Surg (2005) 3(4):268–77. doi: 10.1016/j.ijsu.2005.05.002 PubMed DOI

Lo Nigro C, Macagno M, Sangiolo D, Bertolaccini L, Aglietta M, Merlano MC. NK-Mediated Antibody-Dependent Cell-Mediated Cytotoxicity in Solid Tumors: Biological Evidence and Clinical Perspectives. Ann Transl Med (2019). doi: 10.21037/atm.2019.01.42 PubMed DOI PMC

Sordo-Bahamonde C, Lorenzo-Herrero S, Payer ÁR, Gonzalez S, López-Soto A. Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer. Int J Mol Sci (2020) 21(10):419–26. doi: 10.3390/ijms21103726 PubMed DOI PMC

Ljunggren HG, Kärre K. In Search of the “Missing Self”: MHC Molecules and NK Cell Recognition. Immunol Today (1990) 11(7):237–44. doi: 10.1016/0167-5699(90)90097-s PubMed DOI

Anfossi N, André P, Guia S, Falk CS, Roetynck S, Stewart CA, et al. . Human NK Cell Education by Inhibitory Receptors for MHC Class I. Immun (2006) 25(2):331–42. doi: 10.1016/j.immuni.2006.06.013 PubMed DOI

He Y, Tian Z. NK Cell Education via Nonclassical MHC and Non-MHC Ligands. Cell Mol Immunol (2017) 14(4):321–30. doi: 10.1038/cmi.2016.26 PubMed DOI PMC

Leung KK, Wilson GM, Kirkemo LL, Riley NM, Coon JJ, Wells JA. Broad and Thematic Remodeling of the Surfaceome and Glycoproteome on Isogenic Cells Transformed With Driving Proliferative Oncogenes. Proc Natl Acad Sci (2020) 117(14):7764–75. doi: 10.1073/pnas.1917947117 PubMed DOI PMC

Algarra I, Cabrera T, Garrido F. The HLA Crossroad in Tumor Immunology. Hum Immunol (2000) 61(1):65–73. doi: 10.1016/s0198-8859(99)00156-1 PubMed DOI

Khanna R. Tumour Surveillance: Missing Peptides and MHC Molecules. Immunol Cell Biol (1998) 76(1):20–6. doi: 10.1046/j.1440-1711.1998.00717.x PubMed DOI

Cao Y, Wang X, Jin T, Tian Y, Dai C, Widarma C, et al. . Immune Checkpoint Molecules in Natural Killer Cells as Potential Targets for Cancer Immunotherapy. Signal Transduct Target Ther (2020) 5(1):1–19. doi: 10.1038/s41392-020-00348-8 PubMed DOI PMC

Sivori S, Vacca P, Del Zotto G, Munari E, Mingari MC, Moretta L. Human NK Cells: Surface Receptors, Inhibitory Checkpoints, and Translational Applications. Cell Mol Immunol (2019) 16(5):430–41. doi: 10.1038/s41423-019-0206-4 PubMed DOI PMC

Zheng Y, Ma X, Su D, Zhang Y, Yu L, Jiang F, et al. . The Roles of Siglec7 and Siglec9 on Natural Killer Cells in Virus Infection and Tumour Progression. J Immunol Res (2020) 2020:1–9. doi: 10.1155/2020/6243819 PubMed DOI PMC

Sun H, Huang Q, Huang M, Wen H, Lin R, Zheng M, et al. . Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma. Hepatol Baltim Md (2019) 70(1):168–83. doi: 10.1002/hep.30347 PubMed DOI

Long EO, Rajagopalan S. Stress Signals Activate Natural Killer Cells. J Exp Med (2002) 196(11):1399–402. doi: 10.1084/jem.20021747 PubMed DOI PMC

Chan CJ, Smyth MJ, Martinet L. Molecular Mechanisms of Natural Killer Cell Activation in Response to Cellular Stress. Cell Death Differ (2014) 21(1):5–14. doi: 10.1038/cdd.2013.26 PubMed DOI PMC

Luetke-Eversloh M, Hammer Q, Durek P, Nordström K, Gasparoni G, Pink M, et al. . Human Cytomegalovirus Drives Epigenetic Imprinting of the IFNG Locus in NKG2Chi Natural Killer Cells. PloS Pathog (2014) 10(10):e1004441. doi: 10.1371/journal.ppat.1004441 PubMed DOI PMC

Liu LL, Landskron J, Ask EH, Enqvist M, Sohlberg E, Traherne JA, et al. . Critical Role of CD2 Co-Stimulation in Adaptive Natural Killer Cell Responses Revealed in NKG2C-Deficient Humans. Cell Rep (2016) 15(5):1088–99. doi: 10.1016/j.celrep.2016.04.005 PubMed DOI PMC

Wu N, Veillette A. SLAM Family Receptors in Normal Immunity and Immune Pathologies. Curr Opin Immunol (2016) 38:45–51. doi: 10.1016/j.coi.2015.11.003 PubMed DOI

Barrow AD, Colonna M. Exploiting NK Cell Surveillance Pathways for Cancer Therapy. Cancers (2019) 11(1):55. doi: 10.3390/cancers11010055 PubMed DOI PMC

Raulet DH, Guerra N. Oncogenic Stress Sensed by the Immune System: Role of NK Cell Receptors. Nat Rev Immunol (2009) 9(8):568–80. doi: 10.1038/nri2604 PubMed DOI PMC

Della Chiesa M, Sivori S, Carlomagno S, Moretta L, Moretta A. Activating KIRs and NKG2C in Viral Infections: Toward NK Cell Memory? Front Immunol (2015) 6. doi: 10.3389/fimmu.2015.00573 PubMed DOI PMC

Alari-Pahissa E, Grandclément C, Jeevan-Raj B, Leclercq G, Veillette A, Held W. Activation by SLAM Family Receptors Contributes to NK Cell Mediated “Missing-Self” Recognition. PloS One (2016) 11(4):e0153236. doi: 10.1371/journal.pone.0153236 PubMed DOI PMC

Veillette A. NK Cell Regulation by SLAM Family Receptors and SAP-Related Adapters. Immunol Rev (2006) 214:22–34. doi: 10.1111/j.1600-065X.2006.00453.x PubMed DOI

Ramírez-Ramírez D, Padilla-Castañeda S, Galán-Enríquez CS, Vadillo E, Prieto-Chávez JL, Jiménez-Hernández E, et al. . CRTAM+ NK Cells Endowed With Suppressor Properties Arise in Leukemic Bone Marrow. J Leukoc Biol (2019) 105(5):999–1013. doi: 10.1002/JLB.MA0618-231R PubMed DOI

Ogasawara K, Yoshinaga SK, Lanier LL. Inducible Costimulator Costimulates Cytotoxic Activity and IFN-γ Production in Activated Murine NK Cells. J Immunol (2002) 169(7):3676–85. doi: 10.4049/jimmunol.169.7.3676 PubMed DOI

Schlaphoff V, Lunemann S, Suneetha PV, Jaroszewicz J, Grabowski J, Dietz J, et al. . Dual Function of the NK Cell Receptor 2b4 (CD244) in the Regulation of HCV-Specific CD8+ T Cells. PloS Pathog (2011) 7(5):e1002045. doi: 10.1371/journal.ppat.1002045 PubMed DOI PMC

Ho EL, Carayannopoulos LN, Poursine-Laurent J, Kinder J, Plougastel B, Smith HRC, et al. . Costimulation of Multiple NK Cell Activation Receptors by NKG2D. J Immunol (2002) 169(7):3667–75. doi: 10.4049/jimmunol.169.7.3667 PubMed DOI

Zambello R, Barilà G, Manni S, Piazza F, Semenzato G. NK Cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias. Cells (2020) 9(3):768. doi: 10.3390/cells9030768 PubMed DOI PMC

Mallone R, Funaro A, Zubiaur M, Baj G, Ausiello CM, Tacchetti C, et al. . Signaling Through CD38 Induces NK Cell Activation. Int Immunol (2001) 13(4):397–409. doi: 10.1093/intimm/13.4.397 PubMed DOI

Takeda K, Oshima H, Hayakawa Y, Akiba H, Atsuta M, Kobata T, et al. . CD27-Mediated Activation of Murine NK Cells. J Immunol (2000) 164(4):1741–5. doi: 10.4049/jimmunol.164.4.1741 PubMed DOI

Galán-Díez M, Cuesta-Domínguez Á, Kousteni S. The Bone Marrow Microenvironment in Health and Myeloid Malignancy. Cold Spring Harb Perspect Med (2018) 8(7):a031328. doi: 10.1101/cshperspect.a031328 PubMed DOI PMC

Manier S, Sacco A, Leleu X, Ghobrial IM, Roccaro AM. Bone Marrow Microenvironment in Multiple Myeloma Progression. J BioMed Biotechnol (2012) 2012:157496. doi: 10.1155/2012/157496 PubMed DOI PMC

Cheng H, Sun G, Cheng T. Hematopoiesis and Microenvironment in Hematological Malignancies. Cell Regen (2018) 7(1):22–6. doi: 10.1016/j.cr.2018.08.002 PubMed DOI PMC

Ghobrial IM, Detappe A, Anderson KC, Steensma DP. The Bone-Marrow Niche in MDS and MGUS: Implications for AML and MM. Nat Rev Clin Oncol (2018) 15(4):219–33. doi: 10.1038/nrclinonc.2017.197 PubMed DOI

Zavidij O, Haradhvala NJ, Mouhieddine TH, Sklavenitis-Pistofidis R, Cai S, Reidy M, et al. . Single-Cell RNA Sequencing Reveals Compromised Immune Microenvironment in Precursor Stages of Multiple Myeloma. Nat Cancer (2020) 1(5):493–506. doi: 10.1038/s43018-020-0053-3 PubMed DOI PMC

Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, et al. . BM Mesenchymal Stromal Cell–Derived Exosomes Facilitate Multiple Myeloma Progression. J Clin Invest (2013) 123(4):1542–55. doi: 10.1172/JCI66517 PubMed DOI PMC

Psaila B, Lyden D. The Metastatic Niche: Adapting the Foreign Soil. Nat Rev Cancer (2009) 9(4):285–93. doi: 10.1038/nrc2621 PubMed DOI PMC

García-Ortiz A, Rodríguez-García Y, Encinas J, Maroto-Martín E, Castellano E, Teixidó J, et al. . The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression. Cancers (2021) 13(2):217. doi: 10.3390/cancers13020217 PubMed DOI PMC

Robak P, Węgłowska E, Dróżdż I, Mikulski D, Jarych D, Ferlińska M, et al. . Cytokine and Chemokine Profile in Patients With Multiple Myeloma Treated With Bortezomib. Mediators Inflamm (2020) 2020:1835836. doi: 10.1155/2020/1835836 PubMed DOI PMC

Cao Y, Luetkens T, Kobold S, Hildebrandt Y, Gordic M, Lajmi N, et al. . The Cytokine/Chemokine Pattern in the Bone Marrow Environment of Multiple Myeloma Patients. Exp Hematol (2010) 38(10):860–7. doi: 10.1016/j.exphem.2010.06.012 PubMed DOI

Botta C, Gullà A, Correale P, Tagliaferri P, Tassone P. Myeloid-Derived Suppressor Cells in Multiple Myeloma: Pre-Clinical Research and Translational Opportunities. Front Oncol (2014) 4:348. doi: 10.3389/fonc.2014.00348 PubMed DOI PMC

Lorenzo-Sanz L, Muñoz P. Tumor-Infiltrating Immunosuppressive Cells in Cancer-Cell Plasticity, Tumor Progression and Therapy Response. Cancer Microenviron (2019) 12(2-3):119–32. doi: 10.1007/s12307-019-00232-2 PubMed DOI PMC

Zheng MM, Zhang Z, Bemis K, Belch AR, Pilarski LM, Shively JE, et al. . The Systemic Cytokine Environment Is Permanently Altered in Multiple Myeloma. PloS One (2013) 8(3):e58504. doi: 10.1371/journal.pone.0058504 PubMed DOI PMC

Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S, et al. . Bone Marrow Mesenchymal Stem Cells are Abnormal in Multiple Myeloma. Leuk Off J Leuk Soc Am Leuk Res Fund UK (2007) 21(5):1079–88. doi: 10.1038/sj.leu.2404621 PubMed DOI PMC

Garayoa M, Garcia JL, Santamaria C, Garcia-Gomez A, Blanco JF, Pandiella A, et al. . Mesenchymal Stem Cells From Multiple Myeloma Patients Display Distinct Genomic Profile as Compared With Those From Normal Donors. Leukemia (2009) 23(8):1515–27. doi: 10.1038/leu.2009.65 PubMed DOI

de Jong MME, Kellermayer Z, Papazian N, Tahri S, Hofste op Bruinink D, Hoogenboezem R, et al. . The Multiple Myeloma Microenvironment is Defined by an Inflammatory Stromal Cell Landscape. Nat Immunol (2021) 22(6):769–80. doi: 10.1038/s41590-021-00931-3 PubMed DOI

Fairfield H, Costa S, Falank C, Farrell M, Murphy CS, D’Amico A, et al. . Multiple Myeloma Cells Alter Adipogenesis, Increase Senescence-Related and Inflammatory Gene Transcript Expression, and Alter Metabolism in Preadipocytes. Front Oncol (2021) 10:584683. doi: 10.3389/fonc.2020.584683 PubMed DOI PMC

Adamik J, Galson DL, Roodman GD. Osteoblast Suppression in Multiple Myeloma Bone Disease. J Bone Oncol (2018) 13:62–70. doi: 10.1016/j.jbo.2018.09.001 PubMed DOI PMC

Trotter TN, Gibson JT, Sherpa TL, Gowda PS, Peker D, Yang Y. Adipocyte-Lineage Cells Support Growth and Dissemination of Multiple Myeloma in Bone. Am J Pathol (2016) 186(11):3054–63. doi: 10.1016/j.ajpath.2016.07.012 PubMed DOI PMC

Giuliani N, Rizzoli V, Roodman GD. Multiple Myeloma Bone Disease: Pathophysiology of Osteoblast Inhibition. Blood (2006) 108(13):3992–6. doi: 10.1182/blood-2006-05-026112 PubMed DOI

Gooding S, Olechnowicz SWZ, Morris EV, Armitage AE, Arezes J, Frost J, et al. . Transcriptomic Profiling of the Myeloma Bone-Lining Niche Reveals BMP Signalling Inhibition to Improve Bone Disease. Nat Commun (2019) 10(1):4533. doi: 10.1038/s41467-019-12296-1 PubMed DOI PMC

Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in Biology of Multiple Myeloma: Clinical Applications. Blood (2004) 104(3):607–18. doi: 10.1182/blood-2004-01-0037 PubMed DOI

Pagnucco G, Cardinale G, Gervasi F. Targeting Multiple Myeloma Cells and Their Bone Marrow Microenvironment. Ann NY Acad Sci (2004) 1028:390–9. doi: 10.1196/annals.1322.047 PubMed DOI

Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, et al. . Bone Marrow Angiogenesis and Progression in Multiple Myeloma. Br J Haematol (1994) 87(3):503–8. doi: 10.1111/j.1365-2141.1994.tb08304.x PubMed DOI

Vacca A, Ria R, Semeraro F, Merchionne F, Coluccia M, Boccarelli A, et al. . Endothelial Cells in the Bone Marrow of Patients With Multiple Myeloma. Blood (2003) 102(9):3340–8. doi: 10.1182/blood-2003-04-1338 PubMed DOI

Berardi S, Caivano A, Ria R, Nico B, Savino R, Terracciano R, et al. . Four Proteins Governing Overangiogenic Endothelial Cell Phenotype in Patients With Multiple Myeloma are Plausible Therapeutic Targets. Oncogene (2012) 31(18):2258–69. doi: 10.1038/onc.2011.412 PubMed DOI

Colla S, Storti P, Donofrio G, Todoerti K, Bolzoni M, Lazzaretti M, et al. . Low Bone Marrow Oxygen Tension and Hypoxia-Inducible Factor-1α Overexpression Characterize Patients With Multiple Myeloma: Role on the Transcriptional and Proangiogenic Profiles of CD138+ Cells. Leukemia (2010) 24(11):1967–70. doi: 10.1038/leu.2010.193 PubMed DOI

Wang AA, Gommerman JL, Rojas OL. Plasma Cells: From Cytokine Production to Regulation in Experimental Autoimmune Encephalomyelitis. J Mol Biol (2021) 433(1):166655. doi: 10.1016/j.jmb.2020.09.014 PubMed DOI

Pioli PD. Plasma Cells, the Next Generation: Beyond Antibody Secretion. Front Immunol (2019) 10:2768. doi: 10.3389/fimmu.2019.02768 PubMed DOI PMC

Dang VD, Hilgenberg E, Ries S, Shen P, Fillatreau S. From the Regulatory Functions of B Cells to the Identification of Cytokine-Producing Plasma Cell Subsets. Curr Opin Immunol (2014) 28:77–83. doi: 10.1016/j.coi.2014.02.009 PubMed DOI

De Vos J, Thykjaer T, Tarte K, Ensslen M, Raynaud P, Requirand G, et al. . Comparison of Gene Expression Profiling Between Malignant and Normal Plasma Cells With Oligonucleotide Arrays. Oncogene (2002) 21(44):6848–57. doi: 10.1038/sj.onc.1205868 PubMed DOI

Qian B, Pollard JW. Macrophage Diversity Enhances Tumor Progression and Metastasis. Cell (2010) 141(1):39–51. doi: 10.1016/j.cell.2010.03.014 PubMed DOI PMC

Wang H, Hu WM, Xia Z J, Liang Y, Lu Y, Lin Sx, et al. . High Numbers of CD163+ Tumor-Associated Macrophages Correlate With Poor Prognosis in Multiple Myeloma Patients Receiving Bortezomib-Based Regimens. J Cancer (2019) 10(14):3239–45. doi: 10.7150/jca.30102 PubMed DOI PMC

Berardi S, Ria R, Reale A, De Luisi A, Catacchio I, Moschetta M, et al. . Multiple Myeloma Macrophages: Pivotal Players in the Tumor Microenvironment. J Oncol (2013) 2013:183602. doi: 10.1155/2013/183602 PubMed DOI PMC

Favaloro J, Liyadipitiya T, Brown R, Yang S, Suen H, Woodland N, et al. . Myeloid Derived Suppressor Cells Are Numerically, Functionally and Phenotypically Different in Patients With Multiple Myeloma. Leuk Lymphoma (2014) 55(12):2893–900. doi: 10.3109/10428194.2014.904511 PubMed DOI

Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The Immunosuppressive Tumour Network: Myeloid-Derived Suppressor Cells, Regulatory T Cells and Natural Killer T Cells. Immunol (2013) 138(2):105–15. doi: 10.1111/imm.12036 PubMed DOI PMC

Wang Z, Zhang L, Wang H, Xiong S, Li Y, Tao Q, et al. . Tumor-Induced CD14+HLA-DR (-/Low) Myeloid-Derived Suppressor Cells Correlate With Tumor Progression and Outcome of Therapy in Multiple Myeloma Patients. Cancer Immunol Immunother CII (2015) 64(3):389–99. doi: 10.1007/s00262-014-1646-4 PubMed DOI PMC

Giallongo C, Tibullo D, Parrinello NL, La Cava P, Di Rosa M, Bramanti V, et al. . Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) are Increased in Multiple Myeloma and Are Driven by Dysfunctional Mesenchymal Stem Cells (MSC). Oncotarget (2016) 7(52):85764–75. doi: 10.18632/oncotarget.7969 PubMed DOI PMC

Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S. Myeloid-Derived Suppressor Cells Down-Regulate L-Selectin Expression on CD4+ and CD8+ T Cells. J Immunol Baltim Md 1950 (2009) 183(2):937–44. doi: 10.4049/jimmunol.0804253 PubMed DOI PMC

Lu T, Ramakrishnan R, Altiok S, Youn JI, Cheng P, Celis E, et al. . Tumor-Infiltrating Myeloid Cells Induce Tumor Cell Resistance to Cytotoxic T Cells in Mice. J Clin Invest (2011) 121(10):4015–29. doi: 10.1172/JCI45862 PubMed DOI PMC

Nausch N, Galani IE, Schlecker E, Cerwenka A. Mononuclear Myeloid-Derived “Suppressor” Cells Express RAE-1 and Activate Natural Killer Cells. Blood (2008) 112(10):4080–9. doi: 10.1182/blood-2008-03-143776 PubMed DOI PMC

Binsfeld M, Muller J, Lamour V, Veirman KD, Raeve HD, Bellahcène A, et al. . Granulocytic Myeloid-Derived Suppressor Cells Promote Angiogenesis in the Context of Multiple Myeloma. Oncotarget (2016) 7(25):37931–43. doi: 10.18632/oncotarget.9270 PubMed DOI PMC

Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells Through Membrane-Bound TGF-Beta 1. J Immunol Baltim Md 1950 (2009) 182(1):240–9. doi: 10.4049/jimmunol.182.1.240 PubMed DOI

Stiff A, Trikha P, Mundy-Bosse B, McMichael E, Mace TA, Benner B, et al. . Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function. Clin Cancer Res Off J Am Assoc Cancer Res (2018) 24(8):1891–904. doi: 10.1158/1078-0432.CCR-17-0691 PubMed DOI PMC

Wang JN, Cao XX, Zhao AL, Cai H, Wang X, Li J. Increased Activated Regulatory T Cell Subsets and Aging Treg-Like Cells in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: A Case Control Study. Cancer Cell Int (2018) 18:187. doi: 10.1186/s12935-018-0687-8 PubMed DOI PMC

Muthu Raja KR, Rihova L, Zahradova L, Klincova M, Penka M, Hajek R. Increased T Regulatory Cells Are Associated With Adverse Clinical Features and Predict Progression in Multiple Myeloma. PloS One (2012) 7(10):e47077. doi: 10.1371/journal.pone.0047077 PubMed DOI PMC

Prabhala RH, Neri P, Bae JE, Tassone P, Shammas MA, Allam CK, et al. . Dysfunctional T Regulatory Cells in Multiple Myeloma. Blood (2006) 107(1):301–4. doi: 10.1182/blood-2005-08-3101 PubMed DOI PMC

Lad D, Huang Q, Hoeppli R, Garcia R, Xu L, Levings M, et al. . Evaluating the Role of Tregs in the Progression of Multiple Myeloma. Leuk Lymphoma (2019) 60(9):2134–42. doi: 10.1080/10428194.2019.1579324 PubMed DOI

Braga WMT, Atanackovic D, Colleoni GWB. The Role of Regulatory T Cells and TH17 Cells in Multiple Myeloma. Clin Dev Immunol (2012) 2012:293479. doi: 10.1155/2012/293479 PubMed DOI PMC

Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W, et al. . Elevated IL-17 Produced by Th17 Cells Promotes Myeloma Cell Growth and Inhibits Immune Function in Multiple Myeloma. Blood (2010) 115(26):5385–92. doi: 10.1182/blood-2009-10-246660 PubMed DOI PMC

Bryant C, Suen H, Brown R, Yang S, Favaloro J, Aklilu E, et al. . Long-Term Survival in Multiple Myeloma is Associated With a Distinct Immunological Profile, Which Includes Proliferative Cytotoxic T-Cell Clones and a Favourable Treg/Th17 Balance. Blood Cancer J (2013) 3(9):e148. doi: 10.1038/bcj.2013.34 PubMed DOI PMC

Blom B, van Hoeven V, Hazenberg MD. ILCs in Hematologic Malignancies: Tumor Cell Killers and Tissue Healers. Semin Immunol (2019) 41:101279. doi: 10.1016/j.smim.2019.06.002 PubMed DOI

Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, et al. . HLA Class I, NKG2D, and Natural Cytotoxicity Receptors Regulate Multiple Myeloma Cell Recognition by Natural Killer Cells. Blood (2005) 105(1):251–8. doi: 10.1182/blood-2004-04-1422 PubMed DOI

Lotzová E, Savary CA, Herberman RB. Inhibition of Clonogenic Growth of Fresh Leukemia Cells by Unstimulated and IL-2 Stimulated NK Cells of Normal Donors. Leuk Res (1987) 11(12):1059–66. doi: 10.1016/0145-2126(87)90158-5 PubMed DOI

Frohn C, Höppner M, Schlenke P, Kirchner H, Koritke P, Luhm J. Anti-Myeloma Activity of Natural Killer Lymphocytes. Br J Haematol (2002) 119(3):660–4. doi: 10.1046/j.1365-2141.2002.03879.x PubMed DOI

Stabile H, Fionda C, Gismondi A, Santoni A. Role of Distinct Natural Killer Cell Subsets in Anticancer Response. Front Immunol (2017) 8. doi: 10.3389/fimmu.2017.00293 PubMed DOI PMC

Lion E, Willemen Y, Berneman ZN, Van Tendeloo VFI, Smits ELJ. Natural Killer Cell Immune Escape in Acute Myeloid Leukemia. Leukemia (2012) 26(9):2019–26. doi: 10.1038/leu.2012.87 PubMed DOI

Jurisic V, Srdic T, Konjevic G, Markovic O, Colovic M. Clinical Stage-Depending Decrease of NK Cell Activity in Multiple Myeloma Patients. Med Oncol Northwood Lond Engl (2007) 24(3):312–7. doi: 10.1007/s12032-007-0007-y PubMed DOI

Pittari G, Vago L, Festuccia M, Bonini C, Mudawi D, Giaccone L, et al. . Restoring Natural Killer Cell Immunity Against Multiple Myeloma in the Era of New Drugs. Front Immunol (2017) 8. doi: 10.3389/fimmu.2017.01444 PubMed DOI PMC

Carlsten M, Järås M. Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells. Front Immunol (2019) 10. doi: 10.3389/fimmu.2019.02357 PubMed DOI PMC

El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan AW, et al. . The Requirement for DNAM-1, NKG2D, and NKp46 in the Natural Killer Cell-Mediated Killing of Myeloma Cells. Cancer Res (2007) 67(18):8444–9. doi: 10.1158/0008-5472.CAN-06-4230 PubMed DOI

García-Sanz R, González M, Orfão A, Moro MJ, Hernández JM, Borrego D, et al. . Analysis of Natural Killer-Associated Antigens in Peripheral Blood and Bone Marrow of Multiple Myeloma Patients and Prognostic Implications. Br J Haematol (1996) 93(1):81–8. doi: 10.1046/j.1365-2141.1996.4651006.x PubMed DOI

Farnault L, Sanchez C, Baier C, Le Treut T, Costello RT. Hematological Malignancies Escape From NK Cell Innate Immune Surveillance: Mechanisms and Therapeutic Implications. Clin Dev Immunol (2012) 2012:e421702. doi: 10.1155/2012/421702 PubMed DOI PMC

Nersesian S, Schwartz SL, Grantham SR, MacLean LK, Lee SN, Pugh-Toole M, et al. . NK Cell Infiltration is Associated With Improved Overall Survival in Solid Cancers: A Systematic Review and Meta-Analysis. Transl Oncol (2021) 14(1):100930. doi: 10.1016/j.tranon.2020.100930 PubMed DOI PMC

Giles AJ, Chien CD, Reid CM, Fry TJ, Park DM, Kaplan RN, et al. . The Functional Interplay Between Systemic Cancer and the Hematopoietic Stem Cell Niche. Pharmacol Ther (2016) 168:53–60. doi: 10.1016/j.pharmthera.2016.09.006 PubMed DOI PMC

Famularo G, D’Ambrosio A, Quintieri F, Di Giovanni S, Parzanese I, Pizzuto F, et al. . Natural Killer Cell Frequency and Function in Patients With Monoclonal Gammopathies. J Clin Lab Immunol (1992) 37(3):99–109. PubMed

Osterborg A, Nilsson B, Björkholm M, Holm G, Mellstedt H. Natural Killer Cell Activity in Monoclonal Gammopathies: Relation to Disease Activity. Eur J Haematol (1990) 45(3):153–7. doi: 10.1111/j.1600-0609.1990.tb00443.x PubMed DOI

Pazina T, MacFarlane AW, Bernabei L, Dulaimi E, Kotcher R, Yam C, et al. . Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma. Cancers (2021) 13(2):226. doi: 10.3390/cancers13020226 PubMed DOI PMC

Duault C, Kumar A, Taghi Khani A, Lee SJ, Yang L, Huang M, et al. . Activated Natural Killer Cells Predict Poor Clinical Prognosis in High-Risk B- and T-Cell Acute Lymphoblastic Leukemia. Blood (2021) 138(16):1465–80. doi: 10.1182/blood.2020009871 PubMed DOI PMC

Riggan L, Shah S, O’Sullivan TE. Arrested Development: Suppression of NK Cell Function in the Tumor Microenvironment. Clin Transl Immunol (2021) 10(1):e1238. doi: 10.1002/cti2.1238 PubMed DOI PMC

Bi J, Wang X. Molecular Regulation of NK Cell Maturation. Front Immunol (2020) 11. doi: 10.3389/fimmu.2020.01945 PubMed DOI PMC

Miraki-Moud F, Anjos-Afonso F, Hodby KA, Griessinger E, Rosignoli G, Lillington D, et al. . Acute Myeloid Leukemia Does Not Deplete Normal Hematopoietic Stem Cells But Induces Cytopenias by Impeding Their Differentiation. Proc Natl Acad Sci USA (2013) 110(33):13576–81. doi: 10.1073/pnas.1301891110 PubMed DOI PMC

Richards JO, Chang X, Blaser BW, Caligiuri MA, Zheng P, Liu Y. Tumor Growth Impedes Natural-Killer-Cell Maturation in the Bone Marrow. Blood (2006) 108(1):246–52. doi: 10.1182/blood-2005-11-4535 PubMed DOI PMC

Wang X, Zhao XY. Transcription Factors Associated With IL-15 Cytokine Signaling During NK Cell Development. Front Immunol (2021) 12:610789. doi: 10.3389/fimmu.2021.610789 PubMed DOI PMC

Gotthardt D, Trifinopoulos J, Sexl V, Putz EM. JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation. Front Immunol (2019) 10:2590. doi: 10.3389/fimmu.2019.02590 PubMed DOI PMC

Wang Y, Gao A, Zhao H, Lu P, Cheng H, Dong F, et al. . Leukemia Cell Infiltration Causes Defective Erythropoiesis Partially Through MIP-1α/Ccl3. Leukemia (2016) 30(9):1897–908. doi: 10.1038/leu.2016.81 PubMed DOI

Orange JS. Natural Killer Cell Deficiency. J Allergy Clin Immunol (2013) 132(3):515–25. doi: 10.1016/j.jaci.2013.07.020 PubMed DOI PMC

Joshi PC, Zhou X, Cuchens M, Jones Q. Prostaglandin E2 Suppressed IL-15-Mediated Human NK Cell Function Through Down-Regulation of Common Gamma-Chain. J Immunol Baltim Md 1950 (2001) 166(2):885–91. doi: 10.4049/jimmunol.166.2.885 PubMed DOI

Mishra HK, Dixon KJ, Pore N, Felices M, Miller JS, Walcheck B. Activation of ADAM17 by IL-15 Limits Human NK Cell Proliferation. Front Immunol (2021) 12:711621. doi: 10.3389/fimmu.2021.711621 PubMed DOI PMC

Felices M, Lenvik AJ, McElmurry R, et al. . Continuous Treatment With IL-15 Exhausts Human NK Cells via a Metabolic Defect. JCI Insight (2018) 3(3):96219. doi: 10.1172/jci.insight.96219 PubMed DOI PMC

Bębnowska D, Hrynkiewicz R, Grywalska E, Pasiarski M, Sosnowska-Pasiarska B, Smarz-Widelska I, et al. . Immunological Prognostic Factors in Multiple Myeloma. Int J Mol Sci (2021) 22(7):3587. doi: 10.3390/ijms22073587 PubMed DOI PMC

Vacca A, Di Stefano R, Frassanito A, Iodice G, Dammacco F. A Disturbance of the IL-2/IL-2 Receptor System Parallels the Activity of Multiple Myeloma. Clin Exp Immunol (1991) 84(3):429–34. PubMed PMC

Kotlarz D, Ziętara N, Uzel G, Weidemann T, Braun CJ, Diestelhorst J, et al. . Loss-Of-Function Mutations in the IL-21 Receptor Gene Cause a Primary Immunodeficiency Syndrome. J Exp Med (2013) 210(3):433–43. doi: 10.1084/jem.20111229 PubMed DOI PMC

Brady J, Hayakawa Y, Smyth MJ, Nutt SL. IL-21 Induces the Functional Maturation of Murine NK Cells. J Immunol (2004) 172(4):2048–58. doi: 10.4049/jimmunol.172.4.2048 PubMed DOI

Habib T, Nelson A, Kaushansky K. IL-21: A Novel IL-2–Family Lymphokine That Modulates B, T, and Natural Killer Cell Responses. J Allergy Clin Immunol (2003) 112(6):1033–45. doi: 10.1016/j.jaci.2003.08.039 PubMed DOI

Nair S, Fang M, Sigal LJ. The Natural Killer Cell Dysfunction of Aged Mice is Due to the Bone Marrow Stroma and Is Not Restored by IL-15/IL-15rα Treatment. Aging Cell (2015) 14(2):180–90. doi: 10.1111/acel.12291 PubMed DOI PMC

Pedroza-Pacheco I, Shah D, Domogala A, Luevano M, Blundell M, Jackson N, et al. . Regulatory T Cells Inhibit CD34+ Cell Differentiation Into NK Cells by Blocking Their Proliferation. Sci Rep (2016) 6:22097. doi: 10.1038/srep22097 PubMed DOI PMC

Marcoe JP, Lim JR, Schaubert KL, et al. . TGF-β is Responsible for NK Cell Immaturity During Ontogeny and Increased Susceptibility to Infection During Mouse Infancy. Nat Immunol (2012) 13(9):843–50. doi: 10.1038/ni.2388 PubMed DOI PMC

Rolston KVI. Infections in Cancer Patients With Solid Tumors: A Review. Infect Dis Ther (2017) 6(1):69–83. doi: 10.1007/s40121-017-0146-1 PubMed DOI PMC

Nucci M, Anaissie E. Infections in Patients With Multiple Myeloma in the Era of High-Dose Therapy and Novel Agents. Clin Infect Dis Off Publ Infect Dis Soc Am (2009) 49(8):1211–25. doi: 10.1086/605664 PubMed DOI

Zhang S, Liu W, Hu B, Wang P, Lv X, Chen S, et al. . Prognostic Significance of Tumor-Infiltrating Natural Killer Cells in Solid Tumors: A Systematic Review and Meta-Analysis. Front Immunol (2020) 11:1242. doi: 10.3389/fimmu.2020.01242 PubMed DOI PMC

Bernardini G, Antonangeli F, Bonanni V, Santoni A. Dysregulation of Chemokine/Chemokine Receptor Axes and NK Cell Tissue Localization During Diseases. Front Immunol (2016) 7:402. doi: 10.3389/fimmu.2016.00402 PubMed DOI PMC

Walzer T, Chiossone L, Chaix J, Calver A, Carozzo C, Garrigue-Antar L, et al. . Natural Killer Cell Trafficking In Vivo Requires a Dedicated Sphingosine 1-Phosphate Receptor. Nat Immunol (2007) 8(12):1337–44. doi: 10.1038/ni1523 PubMed DOI

Bernardini G, Sciumè G, Bosisio D, Morrone S, Sozzani S, Santoni A. CCL3 and CXCL12 Regulate Trafficking of Mouse Bone Marrow NK Cell Subsets. Blood (2008) 111(7):3626–34. doi: 10.1182/blood-2007-08-106203 PubMed DOI

Mayol K, Biajoux V, Marvel J, Balabanian K, Walzer T. Sequential Desensitization of CXCR4 and S1P5 Controls Natural Killer Cell Trafficking. Blood (2011) 118(18):4863–71. doi: 10.1182/blood-2011-06-362574 PubMed DOI

Ponzetta A, Benigni G, Antonangeli F, Sciumè G, Sanseviero E, Zingoni A, et al. . Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment. Cancer Res (2015) 75(22):4766–77. doi: 10.1158/0008-5472.CAN-15-1320 PubMed DOI

Lim SA, Kim J, Jeon S, Shin MH, Kwon J, Kim TJ, et al. . Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients. Front Immunol (2019) 10:496. doi: 10.3389/fimmu.2019.00496 PubMed DOI PMC

Yao X, Matosevic S. Chemokine Networks Modulating Natural Killer Cell Trafficking to Solid Tumors. Cytokine Growth Factor Rev (2021) 59:36–45. doi: 10.1016/j.cytogfr.2020.12.003 PubMed DOI

Pellegrino A, Antonaci F, Russo F, Merchionne F, Ribatti D, Vacca A, et al. . CXCR3-Binding Chemokines in Multiple Myeloma. Cancer Lett (2004) 207(2):221–7. doi: 10.1016/j.canlet.2003.10.036 PubMed DOI

Bolomsky A, Schreder M, Hübl W, Zojer N, Hilbe W, Ludwig H. Monokine Induced by Interferon Gamma (MIG/CXCL9) Is an Independent Prognostic Factor in Newly Diagnosed Myeloma. Leuk Lymphoma (2016) 57(11):2516–25. doi: 10.3109/10428194.2016.1151511 PubMed DOI

Bonanni V, Antonangeli F, Santoni A, Bernardini G. Targeting of CXCR3 Improves Anti-Myeloma Efficacy of Adoptively Transferred Activated Natural Killer Cells. J Immunother Cancer (2019) 7(1):290. doi: 10.1186/s40425-019-0751-5 PubMed DOI PMC

Nobutani K, Shimono Y, Mizutani K, Ueda Y, Suzuki T, Kitayama M, et al. . Downregulation of CXCR4 in Metastasized Breast Cancer Cells and Implication in Their Dormancy. PloS One (2015) 10(6):e0130032. doi: 10.1371/journal.pone.0130032 PubMed DOI PMC

Bernardini G, Sciumè G, Santoni A. Differential Chemotactic Receptor Requirements for NK Cell Subset Trafficking Into Bone Marrow. Front Immunol (2013) 4:12. doi: 10.3389/fimmu.2013.00012 PubMed DOI PMC

Noda M, Omatsu Y, Sugiyama T, Oishi S, Fujii N, Nagasawa T. CXCL12-CXCR4 Chemokine Signaling Is Essential for NK-Cell Development in Adult Mice. Blood (2011) 117(2):451–8. doi: 10.1182/blood-2010-04-277897 PubMed DOI

Kohli K, Pillarisetty VG, Kim TS. Key Chemokines Direct Migration of Immune Cells in Solid Tumors. Cancer Gene Ther (2021). doi: 10.1038/s41417-021-00303-x PubMed DOI PMC

Lesokhin AM, Bal S, Badros AZ. Lessons Learned From Checkpoint Blockade Targeting PD-1 in Multiple Myeloma. Cancer Immunol Res (2019) 7(8):1224–9. doi: 10.1158/2326-6066.CIR-19-0148 PubMed DOI PMC

Okazaki T, Honjo T. PD-1 and PD-1 Ligands: From Discovery to Clinical Application. Int Immunol (2007) 19(7):813–24. doi: 10.1093/intimm/dxm057 PubMed DOI

Rosenblatt J, Avigan D. Targeting the PD-1/PD-L1 Axis in Multiple Myeloma: A Dream or a Reality? Blood (2017) 129(3):275–9. doi: 10.1182/blood-2016-08-731885 PubMed DOI

Quatrini L, Mariotti FR, Munari E, Tumino N, Vacca P, Moretta L. The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. Cancers (2020) 12(11):E3285. doi: 10.3390/cancers12113285 PubMed DOI PMC

Lee BH, Park Y, Kim JH, Kang KW, Lee SJ, Kim SJ, et al. . PD-L1 Expression in Bone Marrow Plasma Cells as a Biomarker to Predict Multiple Myeloma Prognosis: Developing a Nomogram-Based Prognostic Model. Sci Rep (2020) 10(1):12641. doi: 10.1038/s41598-020-69616-5 PubMed DOI PMC

Tamura H, Ishibashi M, Sunakawa-Kii M, Inokuchi K. PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma. Cancers (2020) 12(4):924. doi: 10.3390/cancers12040924 PubMed DOI PMC

Benson DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, et al. . The PD-1/PD-L1 Axis Modulates the Natural Killer Cell Versus Multiple Myeloma Effect: A Therapeutic Target for CT-011, a Novel Monoclonal Anti–PD-1 Antibody. Blood (2010) 116(13):2286–94. doi: 10.1182/blood-2010-02-271874 PubMed DOI PMC

Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, et al. . PD-1:PD-L Inhibitory Pathway Affects Both CD4(+) and CD8(+) T Cells and Is Overcome by IL-2. Eur J Immunol (2002) 32(3):634–43. doi: 10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9 PubMed DOI

Davis Z, Felices M, Lenvik TR, Badal S, Hinderlie P, Blazar BR, et al. . PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells But Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets. Blood (2019) 134(Supplement_1):621–1. doi: 10.1182/blood-2019-127261 DOI

Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C, et al. . Increased Expression of Programmed Cell Death Protein 1 on NK Cells Inhibits NK-Cell-Mediated Anti-Tumor Function and Indicates Poor Prognosis in Digestive Cancers. Oncogene (2017) 36(44):6143–53. doi: 10.1038/onc.2017.209 PubMed DOI PMC

Laba S, Mallett G, Amarnath S. The Depths of PD-1 Function Within the Tumor Microenvironment Beyond CD8+ T Cells. Semin Cancer Biol (2021) S1044-579X(21):00153–X. doi: 10.1016/j.semcancer.2021.05.022 Published online May 25. PubMed DOI

Iwata T, Kondo Y, Kimura O, Morosawa T, Fujisaka Y, Umetsu T, et al. . PD-L1+MDSCs are Increased in HCC Patients and Induced by Soluble Factor in the Tumor Microenvironment. Sci Rep (2016) 6:39296. doi: 10.1038/srep39296 PubMed DOI PMC

Lu C, Redd PS, Lee JR, Savage N, Liu K. The Expression Profiles and Regulation of PD-L1 in Tumor-Induced Myeloid-Derived Suppressor Cells. OncoImmunol (2016) 5(12):e1247135. doi: 10.1080/2162402X.2016.1247135 PubMed DOI PMC

Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A, et al. . Marrow Stromal Cells Induce B7-H1 Expression on Myeloma Cells, Generating Aggressive Characteristics in Multiple Myeloma. Leukemia (2013) 27(2):464–72. doi: 10.1038/leu.2012.213 PubMed DOI

Chen H, Li M, Sanchez E, Soof CM, Bujarski S, Ng N, et al. . The JAK Inhibitor Blocks PD-L1, PD-L2 and CD44 Expression in Multiple Myeloma (MM) and Sensitizes MM Cells to Lenalidomide and Steroids. Blood (2018) 132(Supplement 1):1910. doi: 10.1182/blood-2018-99-119099 DOI

Lee YS, Choi H, Cho HR, Son WC, Park YS, Kang CD, et al. . Downregulation of NKG2DLs by TGF-β in Human Lung Cancer Cells. BMC Immunol (2021) 22(1):44. doi: 10.1186/s12865-021-00434-8 PubMed DOI PMC

Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, O’Shea MA, et al. . The Common Gamma-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and its Ligands. J Immunol Baltim Md 1950 (2008) 181(10):6738–46. doi: 10.4049/jimmunol.181.10.6738 PubMed DOI

Park IH, Yang HN, Lee KJ, Kim TS, Lee ES, Jung SY, et al. . Tumor-Derived IL-18 Induces PD-1 Expression on Immunosuppressive NK Cells in Triple-Negative Breast Cancer. Oncotarget (2017) 8(20):32722–30. doi: 10.18632/oncotarget.16281 PubMed DOI PMC

Terawaki S, Chikuma S, Shibayama S, Hayashi T, Yoshida T, Okazaki T, et al. . IFN-α Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity. J Immunol Baltim Md 1950 (2011) 186(5):2772–9. doi: 10.4049/jimmunol.1003208 PubMed DOI

Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. . PD-L1 Is a Novel Direct Target of HIF-1α, and its Blockade Under Hypoxia Enhanced MDSC-Mediated T Cell Activation. J Exp Med (2014) 211(5):781–90. doi: 10.1084/jem.20131916 PubMed DOI PMC

Cluff ER, Nolan J, Collins C, Varadaraj A, Rajasekaran N. Hypoxia-Inducible Factor-1α is Upregulated in Natural Killer Cells by Interleukin-2 and Hypoxia via PI3K/mTOR Signaling Pathway. J Immunol (2019) 202(1 Supplement):194.37–7.

Sun C, Xu J, Huang Q, Huang M, Wen H, Zhang C, et al. . High NKG2A Expression Contributes to NK Cell Exhaustion and Predicts a Poor Prognosis of Patients With Liver Cancer. OncoImmunol (2016) 6(1):e1264562. doi: 10.1080/2162402X.2016.1264562 PubMed DOI PMC

Gooden M, Lampen M, Jordanova ES, Leffers N, Trimbos JB, van der Burg SH, et al. . HLA-E Expression by Gynecological Cancers Restrains Tumor-Infiltrating CD8+ T Lymphocytes. Proc Natl Acad Sci USA (2011) 108(26):10656–61. doi: 10.1073/pnas.1100354108 PubMed DOI PMC

Benevolo M, Mottolese M, Tremante E, Rollo F, Diodoro MG, Ercolani C, et al. . High Expression of HLA-E in Colorectal Carcinoma Is Associated With a Favorable Prognosis. J Transl Med (2011) 9:184. doi: 10.1186/1479-5876-9-184 PubMed DOI PMC

Mahaweni NM, Ehlers FAI, Sarkar S, Janssen JWH, Tilanus MGJ, Bos GMJ, et al. . NKG2A Expression Is Not Per Se Detrimental for the Anti-Multiple Myeloma Activity of Activated Natural Killer Cells in an In Vitro System Mimicking the Tumor Microenvironment. Front Immunol (2018) 9:1415. doi: 10.3389/fimmu.2018.01415 PubMed DOI PMC

Kamiya T, Seow SV, Wong D, Robinson M, Campana D. Blocking Expression of Inhibitory Receptor NKG2A Overcomes Tumor Resistance to NK Cells. J Clin Invest (2019) 129(5):2094–106. doi: 10.1172/JCI123955 PubMed DOI PMC

Ruggeri L, Urbani E, André P, Mancusi A, Tosti A, Topini F, et al. . Effects of Anti-NKG2A Antibody Administration on Leukemia and Normal Hematopoietic Cells. Haematologica (2016) 101(5):626–33. doi: 10.3324/haematol.2015.135301 PubMed DOI PMC

Yang Y, Liu Z, Wang H, Zhang G. HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma. Front Oncol (2021) 11:670673. doi: 10.3389/fonc.2021.670673 PubMed DOI PMC

Malmberg KJ, Levitsky V, Norell H, de Matos CT, Carlsten M, Schedvins K, et al. . IFN-Gamma Protects Short-Term Ovarian Carcinoma Cell Lines From CTL Lysis via a CD94/NKG2A-Dependent Mechanism. J Clin Invest (2002) 110(10):1515–23. doi: 10.1172/JCI15564 PubMed DOI PMC

Marchesi M, Andersson E, Villabona L, Seliger B, Lundqvist A, Kiessling R, et al. . HLA-Dependent Tumour Development: A Role for Tumour Associate Macrophages? J Transl Med (2013) 11:247. doi: 10.1186/1479-5876-11-247 PubMed DOI PMC

Bertone S, Schiavetti F, Bellomo R, Vitale C, Ponte M, Moretta L, et al. . Transforming Growth Factor-Beta-Induced Expression of CD94/NKG2A Inhibitory Receptors in Human T Lymphocytes. Eur J Immunol (1999) 29(1):23–9. doi: 10.1002/(SICI)1521-4141(199901)29:01<23::AID-IMMU23>3.0.CO;2-Y PubMed DOI

Hromadnikova I, Pirkova P, Sedlackova L. Influence of In Vitro IL-2 or IL-15 Alone or in Combination With Hsp-70-Derived 14-Mer Peptide (TKD) on the Expression of NK Cell Activatory and Inhibitory Receptors. Mediators Inflamm (2013) 2013:405295. doi: 10.1155/2013/405295 PubMed DOI PMC

Jonges LE, Giezeman-Smits KM, van Vlierberghe RL, Ensink NG, Hagenaars M, Joly E, et al. . NK Cells Modulate MHC Class I Expression on Tumor Cells and Their Susceptibility to Lysis. Immunobiology (2000) 202(4):326–38. doi: 10.1016/s0171-2985(00)80037-6 PubMed DOI

Cornel AM, Mimpen IL, Nierkens S. MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy. Cancers (2020) 12(7):1760. doi: 10.3390/cancers12071760 PubMed DOI PMC

Gao M, Gao L, Yang G, Tao Y, Hou J, Xu H, et al. . Myeloma Cells Resistance to NK Cell Lysis Mainly Involves an HLA Class I-Dependent Mechanism. Acta Biochim Biophys Sin (2014) 46(7):597–604. doi: 10.1093/abbs/gmu041 PubMed DOI

Martínez-Sánchez MV, Periago A, Legaz I, Gimeno L, Mrowiec A, Montes-Barqueros NR, et al. . Overexpression of KIR Inhibitory Ligands (HLA-I) Determines That Immunosurveillance of Myeloma Depends on Diverse and Strong NK Cell Licensing. OncoImmunol (2015) 5(4):e1093721. doi: 10.1080/2162402X.2015.1093721 PubMed DOI PMC

Sarkar S, van Gelder M, Noort W, Xu Y, Rouschop KMA, Groen R, et al. . Optimal Selection of Natural Killer Cells to Kill Myeloma: The Role of HLA-E and NKG2A. Cancer Immunol Immunother CII (2015) 64(8):951–63. doi: 10.1007/s00262-015-1694-4 PubMed DOI PMC

Mahaweni NM, Ehlers FAI, Bos GMJ, Wieten L. Tuning Natural Killer Cell Anti-Multiple Myeloma Reactivity by Targeting Inhibitory Signaling via KIR and NKG2A. Front Immunol (2018) 9:2848. doi: 10.3389/fimmu.2018.02848 PubMed DOI PMC

Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. . Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants. Science (2002) 295(5562):2097–100. doi: 10.1126/science.1068440 PubMed DOI

Felices M, Miller JS. Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise? Clin Cancer Res Off J Am Assoc Cancer Res (2016) 22(21):5161–3. doi: 10.1158/1078-0432.CCR-16-1582 PubMed DOI PMC

Ewen EM, Pahl JHW, Miller M, Watzl C, Cerwenka A. KIR Downregulation by IL-12/15/18 Unleashes Human NK Cells From KIR/HLA-I Inhibition and Enhances Killing of Tumor Cells. Eur J Immunol (2018) 48(2):355–65. doi: 10.1002/eji.201747128 PubMed DOI

Berglund AK, Fisher MB, Cameron KA, Poole EJ, Schnabel LV. Transforming Growth Factor-β2 Downregulates Major Histocompatibility Complex (MHC) I and MHC II Surface Expression on Equine Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Other Phenotypic Cell Surface Markers. Front Vet Sci (2017) 4:84. doi: 10.3389/fvets.2017.00084 PubMed DOI PMC

Harjunpää H, Guillerey C. TIGIT as an Emerging Immune Checkpoint. Clin Exp Immunol (2020) 200(2):108–19. doi: 10.1111/cei.13407 PubMed DOI PMC

Lozano E, Mena MP, Díaz T, Martin-Antonio B, León S, Rodríguez-Lobato LG, et al. . Nectin-2 Expression on Malignant Plasma Cells Is Associated With Better Response to TIGIT Blockade in Multiple Myeloma. Clin Cancer Res Off J Am Assoc Cancer Res (2020) 26(17):4688–98. doi: 10.1158/1078-0432.CCR-19-3673 PubMed DOI

Stamm H, Wellbrock J, Fiedler W. Interaction of PVR/PVRL2 With TIGIT/DNAM-1 as a Novel Immune Checkpoint Axis and Therapeutic Target in Cancer. Mamm Genome Off J Int Mamm Genome Soc (2018) 29(11-12):694–702. doi: 10.1007/s00335-018-9770-7 PubMed DOI

Guillerey C, Harjunpää H, Carrié N, Kassem S, Teo T, Miles K, et al. . TIGIT Immune Checkpoint Blockade Restores CD8+ T-Cell Immunity Against Multiple Myeloma. Blood (2018) 132(16):1689–94. doi: 10.1182/blood-2018-01-825265 PubMed DOI

Mekhloufi A, Kosta A, Stabile H, Molfetta R, Zingoni A, Soriani A, et al. . Bone Marrow Stromal Cell-Derived IL-8 Upregulates PVR Expression on Multiple Myeloma Cells. via NF-kB Transcription Factor Cancers (2020) 12(2):E440. doi: 10.3390/cancers12020440 PubMed DOI PMC

Sarhan D, Cichocki F, Zhang B, Yingst A, Spellman SR, Cooley S, et al. . Adaptive NK Cells With Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells. Cancer Res (2016) 76(19):5696–706. doi: 10.1158/0008-5472.CAN-16-0839 PubMed DOI PMC

Dao TN, Utturkar S, Atallah Lanman N, Matosevic S. TIM-3 Expression Is Downregulated on Human NK Cells in Response to Cancer Targets in Synergy With Activation. Cancers (2020) 12(9):E2417. doi: 10.3390/cancers12092417 PubMed DOI PMC

Liu Z, Xiang C, Han M, Meng N, Luo J, Fu R. Study on Tim3 Regulation of Multiple Myeloma Cell Proliferation via NF-κb Signal Pathways. Front Oncol (2020) 10:584530. doi: 10.3389/fonc.2020.584530 PubMed DOI PMC

Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. . Upregulation of Tim-3 and PD-1 Expression Is Associated With Tumor Antigen-Specific CD8+ T Cell Dysfunction in Melanoma Patients. J Exp Med (2010) 207(10):2175–86. doi: 10.1084/jem.20100637 PubMed DOI PMC

Fu R, Jr, Ding S, Liu C, Liu B, Liu H, Zhaoyun L, et al. . The Role of Decreased TIM-3 Expression of Natural Killer Cells in the Immune Pathogenesis of Severe Aplastic Anemia. Blood (2019) 134(Supplement_1):3747. doi: 10.1182/blood-2019-127769 DOI

Golden-Mason L, McMahan RH, Strong M, Reisdorph R, Mahaffey S, Palmer BE, et al. . Galectin-9 Functionally Impairs Natural Killer Cells in Humans and Mice. J Virol (2013) 87(9):4835–45. doi: 10.1128/JVI.01085-12 PubMed DOI PMC

Xu J, Liu B, Ma S, Zhang J, Ji Y, Xu L, et al. . Characterizing the Tumor Suppressor Role of CEACAM1 in Multiple Myeloma. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol (2018) 45(4):1631–40. doi: 10.1159/000487730 PubMed DOI

Ning J, Yang R, Wang H, Cui L. HMGB1 Enhances Chemotherapy Resistance in Multiple Myeloma Cells by Activating the Nuclear Factor-κb Pathway. Exp Ther Med (2021) 22(1):705. doi: 10.3892/etm.2021.10137 PubMed DOI PMC

Bednarek K, Kostrzewska-Poczekaj M, Szaumkessel M, Kiwerska K, Paczkowska J, Byzia E, et al. . Downregulation of CEACAM6 Gene Expression in Laryngeal Squamous Cell Carcinoma Is an Effect of DNA Hypermethylation and Correlates With Disease Progression. Am J Cancer Res (2018) 8(7):1249–61. PubMed PMC

Fauriat C, Mallet F, Olive D, Costello RT. Impaired Activating Receptor Expression Pattern in Natural Killer Cells From Patients With Multiple Myeloma. Leukemia (2006) 20(4):732–3. doi: 10.1038/sj.leu.2404096 PubMed DOI

Sanchez-Correa B, Morgado S, Gayoso I, Bergua JM, Casado JG, Arcos MJ, et al. . Human NK Cells in Acute Myeloid Leukaemia Patients: Analysis of NK Cell-Activating Receptors and Their Ligands. Cancer Immunol Immunother (2011) 60(8):1195–205. doi: 10.1007/s00262-011-1050-2 PubMed DOI PMC

Costello RT, Boehrer A, Sanchez C, Mercier D, Baier C, Treut T, et al. . Differential Expression of Natural Killer Cell Activating Receptors in Blood Versus Bone Marrow in Patients With Monoclonal Gammopathy. Immunol (2013) 139(3):338–41. doi: 10.1111/imm.12082 PubMed DOI PMC

Raulet DH. Roles of the NKG2D Immunoreceptor and its Ligands. Nat Rev Immunol (2003) 3(10):781–90. doi: 10.1038/nri1199 PubMed DOI

Song H, Kim J, Cosman D, Choi I. Soluble ULBP Suppresses Natural Killer Cell Activity via Down-Regulating NKG2D Expression. Cell Immunol (2006) 239(1):22–30. doi: 10.1016/j.cellimm.2006.03.002 PubMed DOI

Lundholm M, Schröder M, Nagaeva O, Baranov V, Widmark A, Mincheva-Nilsson L, et al. . Prostate Tumor-Derived Exosomes Down-Regulate NKG2D Expression on Natural Killer Cells and CD8+ T Cells: Mechanism of Immune Evasion. PloS One (2014) 9(9):e108925. doi: 10.1371/journal.pone.0108925 PubMed DOI PMC

Groh V, Wu J, Yee C, Spies T. Tumour-Derived Soluble MIC Ligands Impair Expression of NKG2D and T-Cell Activation. Nat (2002) 419(6908):734–8. doi: 10.1038/nature01112 PubMed DOI

Deng W, Gowen BG, Zhang L, et al. . A Shed NKG2D Ligand That Promotes Natural Killer Cell Activation and Tumor Rejection. Sci (2015) 348(6230):136–9. doi: 10.1126/science.1258867 PubMed DOI PMC

Krockenberger M, Dombrowski Y, Weidler C, Ossadnik M, Hönig A, Häusler S, et al. . Macrophage Migration Inhibitory Factor (MIF) Contributes to the Immune Escape of Ovarian Cancer by Downregulating NKG2D. J Immunol Baltim Md 1950 (2008) 180(11):7338–48. PubMed PMC

Zhang J, Han X, Hu X, Jin F, Gao Z, Yin L, et al. . IDO1 Impairs NK Cell Cytotoxicity by Decreasing NKG2D/NKG2DLs. via promoting miR-18a Mol Immunol (2018) 103:144–55. doi: 10.1016/j.molimm.2018.09.011 PubMed DOI

Leivas A, Valeri A, Córdoba L, García-Ortiz A, Ortiz A, Sánchez-Vega L, et al. . NKG2D-CAR-Transduced Natural Killer Cells Efficiently Target Multiple Myeloma. Blood Cancer J (2021) 11(8):146. doi: 10.1038/s41408-021-00537-w PubMed DOI PMC

Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, et al. . CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma. Clin Cancer Res Off J Am Assoc Cancer Res (2008) 14(9):2775–84. doi: 10.1158/1078-0432.CCR-07-4246 PubMed DOI PMC

Veillette A, Guo H. CS1, a SLAM Family Receptor Involved in Immune Regulation, Is a Therapeutic Target in Multiple Myeloma. Crit Rev Oncol Hematol (2013) 88(1):168–77. doi: 10.1016/j.critrevonc.2013.04.003 PubMed DOI

Kikuchi J, Hori M, Iha H, Toyama-Sorimachi N, Hagiwara S, Kuroda Y, et al. . Soluble SLAMF7 Promotes the Growth of Myeloma Cells via Homophilic Interaction With Surface SLAMF7. Leukemia (2020) 34(1):180–95. doi: 10.1038/s41375-019-0525-6 PubMed DOI

Ishibashi M, Soeda S, Sasaki M, Handa H, Imai Y, Tanaka N, et al. . Clinical Impact of Serum Soluble SLAMF7 in Multiple Myeloma. Oncotarget (2018) 9(78):34784–93. doi: 10.18632/oncotarget.26196 PubMed DOI PMC

Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, et al. . Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial. Cancer (2018) 124(20):4032–43. doi: 10.1002/cncr.31680 PubMed DOI

Gormley NJ, Ko CW, Deisseroth A, Nie L, Kaminskas E, Kormanik N, et al. . FDA Drug Approval: Elotuzumab in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma. Clin Cancer Res Off J Am Assoc Cancer Res (2017) 23(22):6759–63. doi: 10.1158/1078-0432.CCR-16-2870 PubMed DOI

Wang Y, Sanchez L, Siegel DS, Wang ML. Elotuzumab for the Treatment of Multiple Myeloma. J Hematol Oncol J Hematol Oncol (2016) 9(1):55. doi: 10.1186/s13045-016-0284-z PubMed DOI PMC

Campbell KS, Cohen AD, Pazina T. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. Front Immunol (2018) 9:2551. doi: 10.3389/fimmu.2018.02551 PubMed DOI PMC

Sun C, Fu B, Gao Y, Liao X, Sun R, Tian Z, et al. . TGF-β1 Down-Regulation of NKG2D/DAP10 and 2B4/SAP Expression on Human NK Cells Contributes to HBV Persistence. PloS Pathog (2012) 8(3):e1002594. doi: 10.1371/journal.ppat.1002594 PubMed DOI PMC

Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, et al. . Transforming Growth Factor Beta 1 Inhibits Expression of NKp30 and NKG2D Receptors: Consequences for the NK-Mediated Killing of Dendritic Cells. Proc Natl Acad Sci USA (2003) 100(7):4120–5. doi: 10.1073/pnas.0730640100 PubMed DOI PMC

McNerney ME, Lee KM, Kumar V. 2b4 (CD244) is a non-MHC Binding Receptor With Multiple Functions on Natural Killer Cells and CD8+ T Cells. Mol Immunol (2005) 42(4):489–94. doi: 10.1016/j.molimm.2004.07.032 PubMed DOI

Garni-Wagner BA, Purohit A, Mathew PA, Bennett M, Kumar V. A Novel Function-Associated Molecule Related to non-MHC-Restricted Cytotoxicity Mediated by Activated Natural Killer Cells and T Cells. J Immunol Baltim Md 1950 (1993) 151(1):60–70. PubMed

Agresta L, Hoebe KHN, Janssen EM. The Emerging Role of CD244 Signaling in Immune Cells of the Tumor Microenvironment. Front Immunol (2018) 9:2809. doi: 10.3389/fimmu.2018.02809 PubMed DOI PMC

Youn JI, Collazo M, Shalova IN, Biswas SK, Gabrilovich DI. Characterization of the Nature of Granulocytic Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice. J Leukoc Biol (2012) 91(1):167–81. doi: 10.1189/jlb.0311177 PubMed DOI PMC

Jing Y, Ni Z, Wu J, Higgins L, Markowski TW, Kaufman DS, et al. . Identification of an ADAM17 Cleavage Region in Human CD16 (Fcγriii) and the Engineering of a Non-Cleavable Version of the Receptor in NK Cells. PloS One (2015) 10(3):e0121788. doi: 10.1371/journal.pone.0121788 PubMed DOI PMC

Mathiot C, Teillaud JL, Elmalek M, Mosseri V, Euller-Ziegler L, Daragon A, et al. . Correlation Between Soluble Serum CD16 (Scd16) Levels and Disease Stage in Patients With Multiple Myeloma. J Clin Immunol (1993) 13(1):41–8. doi: 10.1007/BF00920634 PubMed DOI

Barrow AD, Martin CJ, Colonna M. The Natural Cytotoxicity Receptors in Health and Disease. Front Immunol (2019) 10:909. doi: 10.3389/fimmu.2019.00909 PubMed DOI PMC

Pazina T, Shemesh A, Brusilovsky M, Porgador A, Campbell KS. Regulation of the Functions of Natural Cytotoxicity Receptors by Interactions With Diverse Ligands and Alterations in Splice Variant Expression. Front Immunol (2017) 8:369. doi: 10.3389/fimmu.2017.00369 PubMed DOI PMC

Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, et al. . NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. Immun (2018) 48(2):396–8. doi: 10.1016/j.immuni.2018.01.010 PubMed DOI PMC

Glasner A, Ghadially H, Gur C, Stanietsky N, Tsukerman P, Enk J, et al. . Recognition and Prevention of Tumor Metastasis by the NK Receptor Nkp46/NCR1. J Immunol Baltim Md 1950 (2012) 188(6):2509–15. doi: 10.4049/jimmunol.1102461 PubMed DOI

Han B, Mao FY, Zhao YL, Lv YP, Teng YS, Duan M, et al. . Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated With Tumor Progression in Human Gastric Cancer. J Immunol Res (2018) 2018:6248590. doi: 10.1155/2018/6248590 PubMed DOI PMC

Garcia-Iglesias T, Del Toro-Arreola A, Albarran-Somoza B, Del Toro-Arreola S, Sanchez-Hernandez PE, Ramirez-Dueñas MG, et al. . Low NKp30, NKp46 and NKG2D Expression and Reduced Cytotoxic Activity on NK Cells in Cervical Cancer and Precursor Lesions. BMC Cancer (2009) 9:186. doi: 10.1186/1471-2407-9-186 PubMed DOI PMC

Wu MR, Zhang T, DeMars LR, Sentman CL. B7H6-Specific Chimeric Antigen Receptors Lead to Tumor Elimination and Host Antitumor Immunity. Gene Ther (2015) 22(8):675–84. doi: 10.1038/gt.2015.29 PubMed DOI PMC

Parodi M, Favoreel H, Candiano G, Gaggero S, Sivori S, Mingari MC, et al. . NKp44-NKp44 Ligand Interactions in the Regulation of Natural Killer Cells and Other Innate Lymphoid Cells in Humans. Front Immunol (2019) 10:719. doi: 10.3389/fimmu.2019.00719 PubMed DOI PMC

Pogge von Strandmann E, Shatnyeva O, Hansen HP. NKp30 and its Ligands: Emerging Players in Tumor Immune Evasion From Natural Killer Cells. Ann Transl Med (2015) 3(20):314. doi: 10.3978/j.issn.2305-5839.2015.09.08 PubMed DOI PMC

Schlecker E, Fiegler N, Arnold A, Altevogt P, Rose-John S, Moldenhauer G, et al. . Metalloprotease-Mediated Tumor Cell Shedding of B7-H6, the Ligand of the Natural Killer Cell-Activating Receptor Nkp30. Cancer Res (2014) 74(13):3429–40. doi: 10.1158/0008-5472.CAN-13-3017 PubMed DOI

Fiegler N, Textor S, Arnold A, Rölle A, Oehme I, Breuhahn K, et al. . Downregulation of the Activating NKp30 Ligand B7-H6 by HDAC Inhibitors Impairs Tumor Cell Recognition by NK Cells. Blood (2013) 122(5):684–93. doi: 10.1182/blood-2013-02-482513 PubMed DOI

Wang W, Guo H, Geng J, Zheng X, Wei H, Sun R, et al. . Tumor-Released Galectin-3, a Soluble Inhibitory Ligand of Human NKp30, Plays an Important Role in Tumor Escape From NK Cell Attack. J Biol Chem (2014) 289(48):33311–9. doi: 10.1074/jbc.M114.603464 PubMed DOI PMC

Castriconi R, Dondero A, Bellora F, Moretta L, Castellano A, Locatelli F, et al. . Neuroblastoma-Derived TGF-β1 Modulates the Chemokine Receptor Repertoire of Human Resting NK Cells. J Immunol Baltim Md 1950 (2013) 190(10):5321–8. doi: 10.4049/jimmunol.1202693 PubMed DOI

Balsamo M, Manzini C, Pietra G, Raggi F, Blengio F, Mingari MC, et al. . Hypoxia Downregulates the Expression of Activating Receptors Involved in NK-Cell-Mediated Target Cell Killing Without Affecting ADCC. Eur J Immunol (2013) 43(10):2756–64. doi: 10.1002/eji.201343448 PubMed DOI

Pinheiro PF, Justino GC, Marques MM. NKp30 - A Prospective Target for New Cancer Immunotherapy Strategies. Br J Pharmacol (2020) 177(20):4563–80. doi: 10.1111/bph.15222 PubMed DOI PMC

Viola D, Dona A, Caserta E, Troadec E, Besi F, McDonald T, et al. . Daratumumab Induces Mechanisms of Immune Activation Through CD38+ NK Cell Targeting. Leukemia (2021) 35(1):189–200. doi: 10.1038/s41375-020-0810-4 PubMed DOI PMC

Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. . Daratumumab Depletes CD38+ Immune Regulatory Cells, Promotes T-Cell Expansion, and Skews T-Cell Repertoire in Multiple Myeloma. Blood (2016) 128(3):384–94. doi: 10.1182/blood-2015-12-687749 PubMed DOI PMC

Wang Y, Zhang Y, Hughes T, Zhang J, Caligiuri MA, Benson DM, et al. . Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo Expanded Autologous NK Cells. Clin Cancer Res Off J Am Assoc Cancer Res (2018) 24(16):4006–17. doi: 10.1158/1078-0432.CCR-17-3117 PubMed DOI PMC

Casneuf T, Adams HC, van de Donk NWCJ, Abraham Y, Bald J, Vanhoof G, et al. . Deep Immune Profiling of Patients Treated With Lenalidomide and Dexamethasone With or Without Daratumumab. Leukemia (2021) 35(2):573–84. doi: 10.1038/s41375-020-0855-4 PubMed DOI PMC

Casneuf T, Xu XS, Adams HC, Axel AE, Chiu C, Khan I, et al. . Effects of Daratumumab on Natural Killer Cells and Impact on Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. Blood Adv (2017) 1(23):2105–14. doi: 10.1182/bloodadvances.2017006866 PubMed DOI PMC

Zhu C, Song Z, Wang A, Srinivasan S, Yang G, Greco R, et al. . Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells. Front Immunol (2020) 11:1771. doi: 10.3389/fimmu.2020.01771 PubMed DOI PMC

Pazina T, James AM, MacFarlane AW, Bezman NA, Henning KA, Bee C, et al. . The Anti-SLAMF7 Antibody Elotuzumab Mediates NK Cell Activation Through Both CD16-Dependent and –Independent Mechanisms. OncoImmunol (2017) 6(9):e1339853. doi: 10.1080/2162402X.2017.1339853 PubMed DOI PMC

Yang G, Gao M, Zhang Y, Kong Y, Gao L, Tao Y, et al. . Carfilzomib Enhances Natural Killer Cell-Mediated Lysis of Myeloma Linked With Decreasing Expression of HLA Class I. Oncotarget (2015) 6(29):26982–94. doi: 10.18632/oncotarget.4831 PubMed DOI PMC

Shi J, Tricot GJ, Garg TK, Malaviarachchi PA, Szmania SM, Kellum RE, et al. . Bortezomib Down-Regulates the Cell-Surface Expression of HLA Class I and Enhances Natural Killer Cell-Mediated Lysis of Myeloma. Blood (2008) 111(3):1309–17. doi: 10.1182/blood-2007-03-078535 PubMed DOI PMC

Pellom ST, Dudimah DF, Thounaojam MC, Sayers TJ, Shanker A. Modulatory Effects of Bortezomib on Host Immune Cell Functions. Immunother (2015) 7(9):1011–22. doi: 10.2217/imt.15.66 PubMed DOI PMC

Holstein SA, McCarthy PL. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience. Drugs (2017) 77(5):505–20. doi: 10.1007/s40265-017-0689-1 PubMed DOI PMC

Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, et al. . Mechanism of Action of Immunomodulatory Drugs (IMiDS) in Multiple Myeloma. Leukemia (2010) 24(1):22–32. doi: 10.1038/leu.2009.236 PubMed DOI PMC

Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, et al. . Thalidomide and Immunomodulatory Derivatives Augment Natural Killer Cell Cytotoxicity in Multiple Myeloma. Blood (2001) 98(1):210–6. doi: 10.1182/blood.v98.1.210 PubMed DOI

Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, et al. . Molecular Mechanisms Whereby Immunomodulatory Drugs Activate Natural Killer Cells: Clinical Application. Br J Haematol (2005) 128(2):192–203. doi: 10.1111/j.1365-2141.2004.05286.x PubMed DOI

Besson L, Charrier E, Karlin L, Allatif O, Marçais A, Rouzaire P, et al. . One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy. Front Immunol (2018) 9:704. doi: 10.3389/fimmu.2018.00704 PubMed DOI PMC

Kini Bailur J, Mehta S, Zhang L, Neparidze N, Parker T, Bar N, et al. . Changes in Bone Marrow Innate Lymphoid Cell Subsets in Monoclonal Gammopathy: Target for IMiD Therapy. Blood Adv (2017) 1(25):2343–7. doi: 10.1182/bloodadvances.2017012732 PubMed DOI PMC

Krönke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, et al. . Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells. Science (2014) 343(6168):301–5. doi: 10.1126/science.1244851 PubMed DOI PMC